Primary or Metastatic Tumor in the Liver ParenchymaNCT02692365
Exploratory Study to Determine Tissue Alterations of Advanced Hepatocellular Carcinoma Induced by Electromagnetic Waves of Low Energy Amplitude Modulated to Specific Frequencies During Imaging Study by MRI
A study testing Magnetic Resonance + hemodynamic + infusion of gadolinium in people with Primary or Metastatic Tumor in the Liver Parenchyma, run by Hospital Sirio-Libanes at 1 site in Brazil.
Trial summary
This is an exploratory, national, single-center, open-label study, being conducted at the Institute of Education and Research of the Syrian-Lebanese Hospital in collaboration with the Radiology Institute, the Heart Institute of the Faculty of Medicine of São Paulo, Hospital São Paulo UNIFESP, and the Departments of… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Primary or Metastatic Tumor in the Liver Parenchyma
- What is being tested?
- Magnetic Resonance + hemodynamic + infusion of gadolinium
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteBrazil
- Study dates
- Sep 2015to Jun 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All individuals selected for these studies should be in accordance with the following inclusion criteria:
- Patients must have a diagnosis of HCC.
- Presence of the primary or metastatic tumor at the time of the procedure, at least one (1) measurable lesion by RECIST criteria modified located in the hepatic parenchyma and size> 2 cm.
- Patients with AFP> 400 ng / ml and image feature not need histopathological confirmation. But in patients with active B virus serology, the value of AFP should be greater than 4000 ng / ml. The remaining patients should be histological confirmation of HCC.
- Patients may be in observation or presence of systemic or intra-hepatic treatment.
- Minimum age 18 years.
- be subjected to MRI study without need for sedation.
Who cannot join
- Individuals selected for this study will be excluded if they are in accordance with the following exclusion criteria:
- can not suspend anti-hypertensive drugs or beta blockers for at least 48 hours or be pacemaker carriers or other implantable device.
- Any restriction known to carry out study of magnetic resonance imaging.
- menstrual delay, pregnant or breastfeeding.
- Presence of metal artifacts or implants that can alter the reading of the magnetic signal or heat or move during the MRI procedure.
- Prior allergic Event Knowledge gadolinium or manganese chloride solution.
Trial locations and contacts
1 site in 1 country.
About this study
This is an exploratory, national, single-center, open-label study, being conducted at the Institute of Education and Research of the Syrian-Lebanese Hospital in collaboration with the Radiology Institute, the Heart Institute of the Faculty of Medicine of São Paulo, Hospital São Paulo UNIFESP, and the Departments of Physics and Mathematics at the University of São Paulo in order to detect the presence of calcium flux change, tumor perfusion and electrical properties of tumor tissue when exposed to RF EMF AM by Cancer-frequency specific in patients with advanced HCC and correlate these findings with hemodynamic changes assessed by non-invasive hemodynamic measurements.
This study aims to demonstrate the presence of three mechanisms (hypothesis) that could be involved in the hemodynamic changes and the specific antitumor effect induced by exposure to RF EMF AM cancer-specific frequency. This study is not intended to study a therapeutic or diagnostic procedure. For this reason, will not be considered evolutionary clinical data during and after the intervention of the study.
- Being tested
- Magnetic Resonance + hemodynamic + infusion of gadolinium
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnetic Resonance + hemodynamic + infusion of gadoliniumProcedure or surgery
Also called Magnetic Resonance assessment Hemodynamics + + infusion of manganese chloride
| Study group | Role | What they receive |
|---|---|---|
| Calcium channels | Experimental | Magnetic Resonance assessment Hemodynamics + + infusion of manganese chloride Receives: Procedure: Magnetic Resonance + hemodynamic + infusion of gadolinium |
| Tumor perfusion | Experimental | Magnetic Resonance + hemodynamic + infusion of gadolinium Receives: Procedure: Magnetic Resonance + hemodynamic + infusion of gadolinium |
What is being measured
The primary outcome is the main question the study is designed to answer.
Exploratory study for the determination of tissue changes of advanced hepatocellular carcinoma induced by electromagnetic waves amplitude modulated low energy specific frequencies during image MRIstudy.
Procedure 1 - calcium channel They will be provided for ten (10) patients allocated for this study. Patients will undergo a two (2) studies of MRI with a minimum interval of 7 days between the two studies.
Day - 8: according to a study of MRI and hemodynamic evaluation Procedure 2 - tumor perfusion They will be provided for ten (10) patients allocated for this study. Patients will undergo a two (2) studies of MRI with a minimum interval of 7 days between the two studies.
Day - 1: first study of MRI Day - 8: according to a study of MRI and hemodynamic evaluation Procedure 3 - electrical properties of the tumor and metabolomics Procedure 4 - static magnetic field exposure They will be provided for 20 (twenty) patients allocated for this study. Patients will not be subjected to MRI studies.
Measured: 30 min
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Feb 2016 (estimated)
- Study startSep 2015
- Primary completionMar 2016
- Study completionJun 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primary or Metastatic Tumor in the Liver ParenchymaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital Sirio-Libanes
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Frederico Perego Costa, Hospital Sirio-Libanes
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02692365
- Sponsor's protocol ID
- HSL 2015-75
- Status last verified
- Aug 2016
- First submitted
- 10 Sep 2015
- Last updated
- 19 Aug 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploratory Study to Determine Tissue Alterations of Advanced Hepatocellular Carcinoma Induced by Electromagnetic Waves of Low Energy Amplitude Modulated to Specific Frequencies During Imaging Study by MRI
- ClinicalTrials.gov ID
- NCT02692365
- Acronym / sponsor ID
- HSL 2015-75
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Hospital Sirio-LibanesUniversity, hospital or other
- Study start
- Sep 2015
- Primary completion
- Mar 2016 (actual)
- Study completion
- Jun 2016 (actual)
- First posted
- 26 Feb 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an exploratory, national, single-center, open-label study, being conducted at the Institute of Education and Research of the Syrian-Lebanese Hospital in collaboration with the Radiology Institute, the Heart Institute of the Faculty of Medicine of São Paulo, Hospital São Paulo UNIFESP, and the Departments of Physics and Mathematics at the University of São Paulo in order to detect the presence of calcium flux change, tumor perfusion and electrical properties of tumor tissue when exposed to RF EMF AM by Cancer-frequency specific in patients with advanced HCC and correlate these findings with hemodynamic changes assessed by non-invasive hemodynamic measurements.
This study aims to demonstrate the presence of three mechanisms (hypothesis) that could be involved in the hemodynamic changes and the specific antitumor effect induced by exposure to RF EMF AM cancer-specific frequency. This study is not intended to study a therapeutic or diagnostic procedure. For this reason, will not be considered evolutionary clinical data during and after the intervention of the study.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Calcium channels | Experimental | Procedure: Magnetic Resonance + hemodynamic + infusion of gadoliniumMagnetic Resonance assessment Hemodynamics + + infusion of manganese chloride |
| Tumor perfusion | Experimental | Procedure: Magnetic Resonance + hemodynamic + infusion of gadoliniumMagnetic Resonance + hemodynamic + infusion of gadolinium |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- All individuals selected for these studies should be in accordance with the following inclusion criteria:
- Patients must have a diagnosis of HCC.
- Presence of the primary or metastatic tumor at the time of the procedure, at least one (1) measurable lesion by RECIST criteria modified located in the hepatic parenchyma and size> 2 cm.
- Patients with AFP> 400 ng / ml and image feature not need histopathological confirmation. But in patients with active B virus serology, the value of AFP should be greater than 4000 ng / ml. The remaining patients should be histological confirmation of HCC.
- Patients may be in observation or presence of systemic or intra-hepatic treatment.
Key exclusion criteria (6 listed)
- Individuals selected for this study will be excluded if they are in accordance with the following exclusion criteria:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnetic Resonance + hemodynamic + infusion of gadoliniumAlso: Magnetic Resonance assessment Hemodynamics + + infusion of manganese chloride | Procedure or surgery | Calcium channels, Tumor perfusion |
Primary outcome
Exploratory study for the determination of tissue changes of advanced hepatocellular carcinoma induced by electromagnetic waves amplitude modulated low energy specific frequencies during image MRIstudy.
Time frame: 30 min
Procedure 1 - calcium channel They will be provided for ten (10) patients allocated for this study. Patients will undergo a two (2) studies of MRI with a minimum interval of 7 days between the two studies. Day - 8: according to a study of MRI and hemodynamic evaluation Procedure 2 - tumor perfusion They will be provided for ten (10) patients allocated for this study. Patients will undergo a two (2) studies of MRI with a minimum interval of 7 days between the two studies. Day - 1: first study of MRI Day - 8: according to a study of MRI and hemodynamic evaluation Procedure 3 - electrical properties of the tumor and metabolomics Procedure 4 - static magnetic field exposure They will be provided for 20 (twenty) patients allocated for this study. Patients will not be subjected to MRI studies.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2016.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Magnetic Resonance + hemodynamic + infusion of gadolinium in people with Primary or Metastatic Tumor in the Liver Parenchyma, run by Hospital Sirio-Libanes at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exploratory study for the determination of tissue changes of advanced hepatocellular carcinoma induced by electromagnetic waves amplitude modulated low energy specific frequencies during image MRIstudy. (time frame: 30 min). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2016.